Healthcare - Biotechnology - NASDAQ - US
$ 5.8
-3.65 %
$ 328 M
Market Cap
-6.82
P/E
CASH FLOW STATEMENT
-58.6 M
OPERATING CASH FLOW
52.5 M
INVESTING CASH FLOW
724 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Design Therapeutics, Inc.
| Net Income | -66.9 M |
| Depreciation & Amortization | 537 K |
| Capital Expenditures | -256 K |
| Stock-Based Compensation | 13.1 M |
| Change in Working Capital | 728 K |
| Others | -4.08 M |
| Free Cash Flow | -58.8 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (66.9) | (63.3) | (35.5) | (8.3) | (2.0) |
| Depreciation & Amortization | 0.5 | 0.4 | 0.1 | 5 K | 0 |
| Deferred Income Tax | 0 | 0 | 77 K | 71 K | 0 |
| Stock Based Compensation | 13.1 | 10.9 | 4.7 | 0.5 | 0 |
| Other Operating Activities | (6.1) | (1.3) | 19 K | 38 K | 95 K |
| Change in Working Capital | 0.7 | 2.0 | 1.4 | (0.8) | 1.8 |
| Cash From Operations | (58.6) | (51.3) | (29.4) | (8.7) | (0.1) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.3) | (0.9) | (1.5) | 76 K | 0 |
| Other Items | 52.8 | (220.1) | (52.1) | (33.5) | 0 |
| Cash From Investing Activities | 52.5 | (221.0) | (53.6) | (33.6) | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0.3 | 0.3 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 44.5 | 0.2 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.7 | 0.2 | 124.9 | 1 K | 0 |
| Cash From Financing Activities | 0.7 | 235 | 0.4 | 44.5 | 0.2 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (5.3) | (272.1) | 296.2 | 2.3 | 57 K |
| FREE CASH FLOW | |||||
| Free Cash Flow | (58.8) | (52.2) | (30.9) | (8.7) | (0.1) |